Form 8-K - Current report:
SEC Accession No. 0001193125-24-205347
Filing Date
2024-08-22
Accepted
2024-08-22 16:02:59
Documents
14
Period of Report
2024-08-21
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d98656d8k.htm   iXBRL 8-K 26462
2 EX-4.1 d98656dex41.htm EX-4.1 71740
  Complete submission text file 0001193125-24-205347.txt   242842

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fulc-20240821.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20240821_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20240821_pre.xml EX-101.PRE 11263
16 EXTRACTED XBRL INSTANCE DOCUMENT d98656d8k_htm.xml XML 3636
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 241231971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)